PT2631248T - Tratamento de tumores utilizando um anticorpo anti-l1 específico - Google Patents

Tratamento de tumores utilizando um anticorpo anti-l1 específico

Info

Publication number: PT2631248T
Authority: PT; Portugal
Prior art keywords: antibody; specific anti; tumor treatment; tumor; treatment
Prior art date: 2007-06-15

Application number

PT130000276T

Other languages

English (en)

Inventor

Breitling Frank

Kelm Daniela

Altevogt Peter

Lüttgau Sandra

Krüger Achim

Moldenhauer Gerhard

Bärreiter Silke

Li Yi

Möbius Ulrich

Dr Susanne Sebens Prof

Dr Heiner Schäfer Prof

Original Assignee

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Medigene Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-15

Filing date

2008-06-13

Publication date

2018-02-15

2008-06-13 Application filed by Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Medigene Ag filed Critical Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

2018-02-15 Publication of PT2631248T publication Critical patent/PT2631248T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1089—Electrons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pathology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Radiology & Medical Imaging (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Mycology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Neurology (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)

PT130000276T 2007-06-15 2008-06-13 Tratamento de tumores utilizando um anticorpo anti-l1 específico PT2631248T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US94435907P	2007-06-15	2007-06-15

Publications (1)

Publication Number	Publication Date
PT2631248T true PT2631248T (pt)	2018-02-15

Family

ID=39862994

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT130000276T PT2631248T (pt)	2007-06-15	2008-06-13	Tratamento de tumores utilizando um anticorpo anti-l1 específico
PT87592309T PT2170956E (pt)	2007-06-15	2008-06-13	Tratamento de tumores utilizando um anticorpo anti-l1 específico

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT87592309T PT2170956E (pt)	2007-06-15	2008-06-13	Tratamento de tumores utilizando um anticorpo anti-l1 específico

Country Status (16)

Country	Link
US (3)	US8138313B2 (pt)
EP (2)	EP2170956B1 (pt)
JP (2)	JP5921066B2 (pt)
CA (2)	CA2958672A1 (pt)
CY (2)	CY1115960T1 (pt)
DK (2)	DK2170956T3 (pt)
ES (2)	ES2658342T3 (pt)
HR (2)	HRP20150007T8 (pt)
HU (1)	HUE036490T2 (pt)
LT (1)	LT2631248T (pt)
NO (1)	NO2631248T3 (pt)
PL (2)	PL2631248T3 (pt)
PT (2)	PT2631248T (pt)
SI (2)	SI2170956T1 (pt)
TW (1)	TWI478939B (pt)
WO (1)	WO2008151819A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008201871A1 (en) *	2008-04-16	2009-11-26	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) *	2008-11-27	2010-06-07	한국생명공학연구원	Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
WO2012058627A2 (en) *	2010-10-29	2012-05-03	Miqin Zhang	Pre-targeted nanoparticle system and method for labeling biological particles
WO2014077648A1 (ko)	2012-11-16	2014-05-22	강원대학교산학협력단	인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
MX388698B (es) *	2014-09-30	2025-03-20	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
CA3029653A1 (en)	2016-08-02	2018-02-08	Memorial Sloan-Kettering Cancer Center	Treating metastatic cancer and model systems for metastatic disease
EP3720882A4 (en)	2017-12-05	2021-10-27	The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center	T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE
CN113101364B (zh)	2018-05-29	2023-12-01	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制剂的开发和应用
WO2020003210A1 (en)	2018-06-29	2020-01-02	Kangwon National University University-Industry Cooperation Foundation	Anti-l1cam antibodies and uses thereof
US12600776B2 (en)	2018-10-19	2026-04-14	Cartexell Inc.	Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
WO2020243616A1 (en) *	2019-05-31	2020-12-03	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	E-cadherin activating antibodies and uses thereof
TW202421652A (zh)	2022-09-21	2024-06-01	瑞士商艾爾瑟拉股份有限公司	結合至l1cam之新穎結合分子
IL320220A (en) *	2022-11-09	2025-06-01	Cis Biopharma Ag	Antibodies against L1-CAM and their uses for diagnostic and therapeutic applications
WO2025068389A2 (en)	2023-09-27	2025-04-03	Elthera Ag	L1cam binding molecules for treating hematological malignancy diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) *	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0436597B1 (en)	1988-09-02	1997-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) *	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP0368684B2 (en) *	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5175384A (en) *	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2091824T3 (es)	1989-04-21	1996-11-16	Us Health	Proteina recombinante de fusion toxina anticuerpo.
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
IE911922A1 (en)	1990-06-07	1991-12-18	Scripps Clinic Res	Apo ai polypeptides, diagnostic methods and systems for¹quantifying apo ai, and therapeutic methods
EP0585287B1 (en)	1990-07-10	1999-10-13	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) *	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) *	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en)	1991-03-01	1993-12-29	Dyax Corp.	Process for the development of binding mini-proteins
DK0580737T3 (da)	1991-04-10	2004-11-01	Scripps Research Inst	Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP1400536A1 (en) *	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
AU665025B2 (en)	1991-09-23	1995-12-14	Cambridge Antibody Technology Limited	Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de)	1991-11-25	2002-05-29	Enzon Inc	Multivalente antigen-bindende proteine
ATE244763T1 (de) *	1992-02-11	2003-07-15	Cell Genesys Inc	Erzielen von homozygotem durch zielgerichtete genetische ereignisse
WO1994004189A1 (en)	1992-08-25	1994-03-03	Medac Gesellschaft Fur Klinische Spezialpräparate Mbh	Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
US6811779B2 (en) *	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6114507A (en) *	1995-06-30	2000-09-05	Mochida Pharmaceutical Co., Ltd.	Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US5837283A (en)	1997-03-12	1998-11-17	The Regents Of The University Of California	Cationic lipid compositions targeting angiogenic endothelial cells
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
CA2340091C (en) *	1998-08-11	2013-02-05	Idec Pharmaceuticals Corporation	Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
DE60036935T2 (de) *	2000-07-10	2008-08-21	Mor-Research Applications Ltd.	Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
DE60124912T2 (de)	2001-09-14	2007-06-14	Affimed Therapeutics Ag	Multimerische, einzelkettige, Tandem-Fv-Antikörper
GB0209893D0 (en) *	2002-04-30	2002-06-05	Molmed Spa	Conjugate
KR100470535B1 (ko)	2002-06-27	2005-02-22	재단법인서울대학교산학협력재단	유피에이 항체 부착 이뮤노리포좀
WO2004037198A2 (en)	2002-10-24	2004-05-06	The Board Of Trustees Of The University Of Illinois	Antibody-mediated induction of tumor cell death
US20040202666A1 (en)	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
GB0306618D0 (en)	2003-03-22	2003-04-30	Univ Newcastle	Antibody
EP1623995A1 (en)	2004-08-06	2006-02-08	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Inhibitors of L1 and ADAM10 for the treatment of carcinomas
US20090304721A1 (en)	2005-09-07	2009-12-10	Medlmmune, Inc	Toxin conjugated eph receptor antibodies
WO2007114550A1 (en) *	2006-04-03	2007-10-11	Korea Research Institute Of Bioscience And Biotechnology	A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
EP2054083B1 (en) *	2006-08-23	2013-11-27	Korea Research Institute of Bioscience and Biotechnology	A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
AU2007221863A1 (en)	2006-10-16	2008-05-01	Deutsches Krebsforschungszentrum Stiftung Des Offenftlichen Rechts	Treatment of chemotherapy -or radiothereapy-resistant tumors

2008
- 2008-06-13 PL PL13000027T patent/PL2631248T3/pl unknown
- 2008-06-13 LT LTEP13000027.6T patent/LT2631248T/lt unknown
- 2008-06-13 EP EP08759230.9A patent/EP2170956B1/en not_active Not-in-force
- 2008-06-13 ES ES13000027.6T patent/ES2658342T3/es active Active
- 2008-06-13 WO PCT/EP2008/004773 patent/WO2008151819A2/en not_active Ceased
- 2008-06-13 PT PT130000276T patent/PT2631248T/pt unknown
- 2008-06-13 TW TW097122231A patent/TWI478939B/zh not_active IP Right Cessation
- 2008-06-13 ES ES08759230.9T patent/ES2528167T3/es active Active
- 2008-06-13 EP EP13000027.6A patent/EP2631248B9/en not_active Not-in-force
- 2008-06-13 JP JP2010511542A patent/JP5921066B2/ja not_active Expired - Fee Related
- 2008-06-13 PT PT87592309T patent/PT2170956E/pt unknown
- 2008-06-13 DK DK08759230.9T patent/DK2170956T3/en active
- 2008-06-13 SI SI200831362T patent/SI2170956T1/sl unknown
- 2008-06-13 CA CA2958672A patent/CA2958672A1/en not_active Abandoned
- 2008-06-13 CA CA2691075A patent/CA2691075C/en not_active Expired - Fee Related
- 2008-06-13 PL PL08759230T patent/PL2170956T3/pl unknown
- 2008-06-13 US US12/139,006 patent/US8138313B2/en not_active Expired - Fee Related
- 2008-06-13 NO NO13000027A patent/NO2631248T3/no unknown
- 2008-06-13 HR HRP20150007TT patent/HRP20150007T8/hr unknown
- 2008-06-13 DK DK13000027.6T patent/DK2631248T3/en active
- 2008-06-13 HU HUE13000027A patent/HUE036490T2/hu unknown
- 2008-06-13 SI SI200831916T patent/SI2631248T1/en unknown
2012
- 2012-02-06 US US13/367,178 patent/US8580258B2/en not_active Expired - Fee Related
2013
- 2013-10-03 US US14/045,019 patent/US9260521B2/en not_active Expired - Fee Related
2014
- 2014-10-01 JP JP2014202878A patent/JP6042395B2/ja not_active Expired - Fee Related
2015
- 2015-01-22 CY CY20151100066T patent/CY1115960T1/el unknown
2018
- 2018-02-01 HR HRP20180192TT patent/HRP20180192T1/hr unknown
- 2018-02-05 CY CY20181100143T patent/CY1119890T1/el unknown

Also Published As

Publication number	Publication date
US20120258039A1 (en)	2012-10-11
US20140120117A1 (en)	2014-05-01
JP6042395B2 (ja)	2016-12-14
EP2631248B9 (en)	2018-05-23
HRP20150007T1 (hr)	2015-03-13
JP5921066B2 (ja)	2016-05-24
EP2631248A2 (en)	2013-08-28
DK2631248T3 (en)	2018-02-12
CA2691075A1 (en)	2008-12-18
US8138313B2 (en)	2012-03-20
PL2170956T3 (pl)	2015-04-30
LT2631248T (lt)	2018-04-25
WO2008151819A2 (en)	2008-12-18
EP2170956A2 (en)	2010-04-07
ES2658342T9 (es)	2018-06-06
ES2528167T3 (es)	2015-02-04
US20090162355A1 (en)	2009-06-25
EP2631248B1 (en)	2017-11-15
TWI478939B (zh)	2015-04-01
JP2015042651A (ja)	2015-03-05
WO2008151819A3 (en)	2009-04-09
SI2170956T1 (sl)	2015-02-27
HUE036490T2 (hu)	2018-07-30
EP2631248A3 (en)	2013-10-23
DK2170956T3 (en)	2015-02-02
US8580258B2 (en)	2013-11-12
EP2170956B1 (en)	2014-10-22
CA2691075C (en)	2017-04-11
CA2958672A1 (en)	2008-12-18
CY1119890T1 (el)	2018-06-27
US9260521B2 (en)	2016-02-16
ES2658342T3 (es)	2018-03-09
TW200918556A (en)	2009-05-01
HRP20150007T8 (hr)	2015-08-14
PT2170956E (pt)	2015-02-05
SI2631248T1 (en)	2018-04-30
JP2010529970A (ja)	2010-09-02
HRP20180192T1 (hr)	2018-04-06
CY1115960T1 (el)	2017-01-25
PL2631248T3 (pl)	2018-06-29
NO2631248T3 (pt)	2018-04-14

Publication	Publication Date	Title
PT2631248T (pt)	2018-02-15	Tratamento de tumores utilizando um anticorpo anti-l1 específico
EP2341974A4 (en)	2012-04-04	CATHETER ARRANGEMENT
IL197217B (en)	2019-12-31	Novel anti-cd38 antibodies for the treatment of cancer
EP2125100A4 (en)	2010-03-24	Muscle
IL243376A0 (en)	2016-02-29	Antagonist antibody against epha2 for the treatment of cancer
EP2134446A4 (en)	2011-04-06	BIOGAS PROCESSING
BRPI0810206A2 (pt)	2014-10-21	Método de tratar câncer
PT2115472E (pt)	2014-02-14	Biomarcadores de cancro
DK3457135T3 (da)	2025-02-24	Behandlingsmuligheder til fabrys sygdom
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
EP2219750A4 (en)	2013-01-23	PLAYING SET-SLIDE
EP2176032A4 (en)	2016-03-23	BACK ARRANGEMENT
BRPI0910854A2 (pt)	2015-10-06	métodos de tratamento
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
DK2035369T3 (da)	2014-10-06	Terapeutiske
EP2033578A4 (en)	2010-10-06	Lancet assembly
EP2012795A4 (en)	2009-07-22	THERAPEUTIC TRITERPENOIDS
DK2173831T3 (da)	2012-09-17	Brøndbehandling
BRPI0810559A2 (pt)	2015-02-10	Macadores de doenças
DK2147122T3 (da)	2014-10-13	Enzymatisk kræftbehandling
EP2277400A4 (en)	2012-01-25	MAGNETIC THERAPY SHOE
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
EP2008586A4 (en)	2010-10-06	Lancet assembly
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos